|
1
|
Wang Y, Wu L, Wang H, Jiang M, Chen Y, Zheng X, Li L, Yin Q, Han L, Bai L, Bian Y. Ligusticum chuanxiong: a chemical, pharmacological and clinical review. Front Pharmacol 2025; 16:1523176. [PMID: 40235541 PMCID: PMC11996930 DOI: 10.3389/fphar.2025.1523176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2024] [Accepted: 03/21/2025] [Indexed: 04/17/2025] Open
Abstract
Ethnopharmacological Relevance The dried rhizome of Ligusticum chuanxiong S.H.Qiu, Y.Q.Zeng, K.Y.Pan, Y.C.Tang and J.M.Xu (Apiaceae; including the horticultural variety Ligusticum chuanxiong Hort.) [synonym: Conioselinum anthriscoides (H.Boissieu) Pimenov and Kljuykov (The taxonomic classification has been adopted by the World Checklist of Vascular Plants)] is a traditional Chinese botanical drug renowned for its anti-inflammatory and antioxidant properties. It has been widely used to treatment various diseases, particularly cardio-cerebral vascular diseases (CCVDs). Aim of the review This review aims to summarize recent advances in Ligusticum chuanxiong (CX) research, including its chemical composition and pharmacological effects, and modern clinical applications. Materials and methods A systematic literature search was conducted using keywords such as "Chuanxiong," "traditional Chinese medicine," "chemical components," "metabolites," "CCVDs," and "pharmacological effects" to identify relevant literature published between 2014 and 2025. Databases including PubMed, Web of Science, Google Scholar, and CNKI were utilized. Chemical structures in SMILES format were retrieved from the PubChem, and two-dimensional chemical structures were generated using ChemDraw Ultra 8.0. Classical prescriptions of chuanxiong were obtained from authoritative traditional Chinese medicine databases. Results Over 100 metabolites have been isolated and identified from CX, classified into nine major classes. Key bioactive compounds include senkyunolide A, ligustilide, tetramethylpyrazine (TMP), and ligusticum CX polysaccharides (LCP). CX demonstrates significant pharmacological effects in treating CCVDs, such as atherosclerosis (AS), myocardial and cerebral ischemia-reperfusion injury, and hypertension. Its therapeutic mechanisms include antiplatelet activity, endothelial cell protection, anti-inflammatory, antioxidant, and anti-apoptotic properties. CX can be administered alone or in combination with other traditional Chinese medicines (TCMs) or chemical drugs, showing efficacy in cardiovascular, nervous system, digestive system disorders, as well as analgesia and anticancer activities. Conclusion CX holds substantial clinical value for treating multi-system diseases, with extensive evidence supporting its use in CCVDs. Further research and clinical exploration of CX are warranted to fully harness its therapeutic potential.
Collapse
Affiliation(s)
- Yin Wang
- Department of Pharmacy, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
- Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Liuyun Wu
- Department of Pharmacy, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
- Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Hulin Wang
- Department of Pharmacy, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
- Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Mingyu Jiang
- School of Pharmacy, North Sichuan Medical Collage, Nanchong, China
| | - Yu Chen
- Power China Chengdu Engineering Corporation Limited, Chengdu, China
| | - Xingyue Zheng
- Department of Pharmacy, Chengdu Women’s and Children’s Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Lian Li
- Department of Pharmacy, The Fourth People’s Hospital of Chengdu, Chengdu, China
| | - Qinan Yin
- Department of Pharmacy, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
- Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Lizhu Han
- Department of Pharmacy, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
- Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Lan Bai
- Department of Pharmacy, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
- Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Yuan Bian
- Department of Pharmacy, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
- Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| |
Collapse
|
|
2
|
Wang X, Yin J, Mao W, Wang Z, Wu S, You Y. Cs 2CO 3 Promoted [4 + 2] Cycloaddition of 1,6-Enynes: An Approach to Tetrahydro-1 H-benzo- f-isoindole Isomers. Org Lett 2024; 26:7757-7762. [PMID: 39267494 DOI: 10.1021/acs.orglett.4c02927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/17/2024]
Abstract
A Cs2CO3-promoted [4 + 2] cycloaddition of 1,6-enynes under mild reaction conditions has been developed. This protocol provides a facile approach to a series of tetrahydro-1H-benzo[f]isoindole isomerized products promoted by Cs2CO3 with moderate to high yields. By simply switching the reaction solvent and controlling the reaction time, two isomerization products could be obtained, both with good selectivity.
Collapse
Affiliation(s)
- Xu Wang
- School of Chemistry and Chemical Engineering, Hefei University of Technology and Anhui Province Key Laboratory of Value-Added Catalytic Conversion and Reaction Engineering, Hefei 230009, China
| | - Junhao Yin
- School of Chemistry and Chemical Engineering, Hefei University of Technology and Anhui Province Key Laboratory of Value-Added Catalytic Conversion and Reaction Engineering, Hefei 230009, China
| | - Wangqin Mao
- School of Chemistry and Chemical Engineering, Hefei University of Technology and Anhui Province Key Laboratory of Value-Added Catalytic Conversion and Reaction Engineering, Hefei 230009, China
| | - Zhenyu Wang
- Anhui Province Key Lab of Green Manufacturing in Phosegene Industry, Caijiashan Fine Chem Pk, Xinhang 242235, Guangde, China
| | - Shuang Wu
- Key Laboratory of Jiangxi Province for Persistent Pollutants Control and Resources Recycle, Nanchang Hangkong University, Nanchang 330063, China
| | - Yang'en You
- School of Chemistry and Chemical Engineering, Hefei University of Technology and Anhui Province Key Laboratory of Value-Added Catalytic Conversion and Reaction Engineering, Hefei 230009, China
- Anhui Province Key Lab of Green Manufacturing in Phosegene Industry, Caijiashan Fine Chem Pk, Xinhang 242235, Guangde, China
| |
Collapse
|
|
3
|
Tian X, Wei J, Zhuang Y, Lin X, Liu L, Xia J, Huai W, Xiong Y, Chen Y. Effectiveness and safety of Chinese herbal footbaths as an adjuvant therapy for dysmenorrhea: a systematic review and meta-analysis. Front Pharmacol 2024; 15:1397359. [PMID: 39161905 PMCID: PMC11331266 DOI: 10.3389/fphar.2024.1397359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2024] [Accepted: 07/16/2024] [Indexed: 08/21/2024] Open
Abstract
Objectives To evaluate the effectiveness and safety of Chinese herbal footbaths (CHF) as an adjunctive therapy in managing dysmenorrhea. Methods Ten electronic databases were searched to identify eligible randomized clinical trials (RCTs) from inception until June 2023. Outcome measurements encompassed the total effective rate, visual analog scale (VAS) score of pain intensity, Cox menstrual symptom scale (CMSS) score, symptom score, Traditional Chinese Medicine (TCM) syndrome scale, and any reported adverse events. The methodological quality of the included studies was assessed with the Cochrane collaboration tool. Review Manager 5.3 software was employed for quantitative synthesis, and funnel plots were utilized to evaluate potential reporting bias. Results Eighteen RCTs with 1,484 dysmenorrhea patients were included. The aggregated results suggested that the adjunctive CHF could significantly ameliorate dysmenorrhea, as evident from the improved total effective rate [risk ratio (RR) 1.18, 95% confidence interval (CI): 1.12 to 1.23, P < 0.00001], VAS (MD 0.88, 95% CI: 0.68 to 1.09, P < 0.00001), CMSS (MD 3.61, 95% CI: 2.73 to 4.49, P < 0.00001), symptom score (SMD 1.09, 95% CI: 0.64 to 1.53, P < 0.00001), and TCM syndrome scale (MD 3.76, 95% CI: 2.53 to 4.99, P < 0.0001). In addition, CHF presented fewer adverse events with a better long-term effect (RR 1.34, 95% CI: 1.11 to 1.63, P < 0.01) and diminished recurrence rate (RR 0.19, 95% CI: 0.09 to 0.39, P < 0.0001). Conclusion Current evidence implies that CHF may be an effective and safe adjunctive therapy for patients with dysmenorrhea. However, the methodological quality of the studies included was undesirable, necessitating further verification with more well-designed and high-quality multicenter RCTs. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=188256, identifier registration number.
Collapse
Affiliation(s)
- Xiaoping Tian
- CDUTCM-KEELE Health and Medical Sciences Institute, School of Basic Medical Sciences, School of Acupuncture, Moxibustion, and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Jingwen Wei
- West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China
| | - Yijia Zhuang
- West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China
| | - Xiaoding Lin
- CDUTCM-KEELE Health and Medical Sciences Institute, School of Basic Medical Sciences, School of Acupuncture, Moxibustion, and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Liu Liu
- CDUTCM-KEELE Health and Medical Sciences Institute, School of Basic Medical Sciences, School of Acupuncture, Moxibustion, and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Jun Xia
- CDUTCM-KEELE Health and Medical Sciences Institute, School of Basic Medical Sciences, School of Acupuncture, Moxibustion, and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Wenying Huai
- CDUTCM-KEELE Health and Medical Sciences Institute, School of Basic Medical Sciences, School of Acupuncture, Moxibustion, and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Ying Xiong
- West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China
| | - Yunhui Chen
- CDUTCM-KEELE Health and Medical Sciences Institute, School of Basic Medical Sciences, School of Acupuncture, Moxibustion, and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| |
Collapse
|